IL1RAP Antibody Shows Early Responses in MDS and AML Cohorts

Company Cantargia Event Type Phase 1b/2a data disclosure (ASH abstract) Modality Monoclonal antibody Asset Nadunolimab (CAN04) Target IL1RAP Disease Area Higher-risk MDS; relapsed/refractory AML Summary Previously missed November 4 issuer disclosure of ASH-abstract data: in an investigator-initiated Phase 1b/2a trial of nadunolimab, seven of ten…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *